Egypt


Welcome to AstraZeneca Egypt

Improving health is one of the toughest challenges facing the world today. As a global, innovation-driven biopharmaceutical company, AstraZeneca has a key contribution to make through the discovery, development, manufacturing and commercialisation of medicines for six important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory and inflammation.

AstraZeneca Egypt is engaged in the manufacture and supply of medicines that aim to make a real difference to the lives of Egyptians. Our business is driven by our mission to bring new innovative medicines into peoples’ lives.

Primary Contact

133, Road 90 North
5th Settlement
New Cairo
Cairo
Tel: +20 2 2598 0222
Fax: +20 2 2598 0225 / 226



Our global focus areas



AstraZeneca Egypt


AstraZeneca has a solid presence in the Egyptian pharmaceutical market since 1968, when Astra opened its first office, followed by Zeneca Scientific in 1972. Today, AstraZeneca Egypt has around 650 employees, including our Commercial and Operations units. We have a special focus on people development as our core belief is that our people are our key assets and key enablers for achieving our bold ambition.

We believe in maintaining high ethical standards of business practice. Aiming to effectively manage that responsibility, we find new ways of bringing benefit to society and thereby ensure that AstraZeneca continues to be welcomed as a valued member of the local community.

Manufacturing Plant

The AstraZeneca Egypt manufacturing facility is fully owned by AstraZeneca, the 6,000-square meter facility is located in Sixth of October City. The plant was inaugurated in 2006, it has a:

  • Formulation capacity of 900 Million tablets, based on 24/5 at 85% working pattern
  • Automatic packing lines: 40 million packs, based on different working patterns of 24/5 & 16/5 at 85%
  • Manual Secondary Packing line: 2 million packs, based on 8/5 at 85% working pattern

It has been designed to formulate tablets using the wet and spray granulation technology. The plant does primary and secondary packaging activities for tablets and devices. The site has quality control, quality assurance, and warehousing capabilities.

The plant is a market access site that supplies the Egyptian health care community with medicines from different therapeutic areas: cardiovascular, gastrointestinal, respiratory, neuroscience and oncology



Our Medicines

Medical Information

Questions or comments on AstraZeneca products and therapeutic areas can be sent to the AZ Medical Information Service at the following address: medinfo-egypt@astrazeneca.com

Product Generic name Therapy area

Arimidex

anastrozole

Oncology

Alvesco

ciclesonide

Respiratory

Atacand

candesartan cilexetil

Cardiovascular

Atacand Plus

candesartan cilexetil/hydrochlorthiazide

Cardiovascular

Bambec

bambuterol

Respiratory

Brilique

ticagrelor

Cardiovascular

Byetta

exanetide

Diabetes

Casodex

bicalutamide

Oncology

Crestor

rosuvastatin

Cardiovascular

Faslodex

fulvestrant

Oncology

Forxiga

dapagliflozin

Diabetes

Imdur

isosorbide-5-mononitrate

Cardiovascular

Inderal

propranolol hydrochloride

Cardiovascular

Iressa

gefinitnib

Oncology

Kombiglyze

Saxagliptin/Metformin

Diabetes

Logimax

felodipine - ramipril

Cardiovascular

Losec

omeprazole

Gastrointestinal

Nexium

esomeprazole

Gastrointestinal

Nolvadex

tamoxifen citrate

Oncology

Onglyza

Saxagliptin

Diabetes

Plendil

felodipine

Cardiovascular

Pulmicort

budesonide

Respiratory

SelokenZOC

Metoprolol

Cardiovascular

Seroquel

quetiapine

Neuroscience

Symbicort

budesonide - formoterol

Respiratory

Tenoret

atetonol – chlorothalidone

Cardiovascular

Tenoretic

atenolol - chlorothalidone

Cardiovascular

Tenormin

atenolol

Cardiovascular

Zestril

lisinopril dihydrate

Cardiovascular

Zestoretic

lisinopril – hydrochlorothiazide

Cardiovascular

Zoladex

goserelin acetate

Oncology

Zomig

zolmitriptan

Neuroscience



Strengthening Healthcare Capabilities


AstraZeneca supports the Egyptian healthcare community through continuous medical education programs in cooperation with international centers of excellence and reputable regional and Egyptian medical societies in the fields of respiratory, cardiovascular-metabolic, gastro-intestinal diseases and oncology.

We are committed to be a partner of choice for the various stakeholders in the Egyptian health care community, we have established partnerships with the Ministry of Health, National Health Insurance and leading scientific societies through the following programs:


Our projects

Pulmo-Aid project

The Pulmo-Aid project for asthma in collaboration with the Ministry of Health and the Egyptian Scientific Society of Bronchology, Pulmo-Aid is a unique continuous medical education project targeting chest hospitals & specialized centers nationwide.

Specialized Hypertension Clinics

In collaboration with the Ministry of Health and the Egyptian Hypertension Society AstraZeneca is establishing specialized Hypertension Clinics in MOH and university hospitals, aiming at reaching a broader patient segment, upgrading knowledge of MOH HCPs in management of Hypertension and enhancing the disease awareness of patients.

I-Protect Project

I-Protect project is an integrated patient-centric initiative by the National Institute of Diabetes and Endocrinology (NIDE) in Egypt, sponsored by AstraZeneca. The project started in 2014 and has been implemented in important centers & hospitals with a plan to cover all geographical regions in Egypt. The main objectives of the Programme are HCP education, patient education and early detection of diabetes complications (retinopathy, nephropathy & neuropathy).

Pharma Excellence - Good Pharmacy Practice

The Pharma Excellence - Good Pharmacy Practice (GPP) project is a 2-year program accredited by St. John’s University, New York, USA in partnership with the Egyptian Syndicate of Pharmacists and the Faculty of Pharmacy at Al-Azhar University. The program aims to improve pharmacy practice through offering courses on drug information center, clinical pharmacy, good storage practices, supply chain management and patient counseling.



Research & Development

AstraZeneca Egypt is striving to become a leader in science through real world studies. Currently, five non-interventional studies and three externally sponsored scientific research programs are rolled out:


Non-Interventional Studies


Cardiovascular-metabolic therapy area:

  • Hypertension: an epidemiological non-interventional study to evaluate response rate to different antihypertensive classes in real life practice.
  • I-Discover: Observational non-interventional study to investigate Type 2 Diabetes and its management in patients initiating a 2nd line monotherapy or add-on to first line.
  • CEPHEUS II: Non-interventional study on the under treatment of dyslipidemia in Egypt. Study final report has been completed and published in Cardiology and Therapy Journal.

Respiratory therapy area:

  • COPVAR: an observational non-interventional study aiming at evaluation of COPD in Middle East & Africa population classes in real life practice.
  • ESMAA - Descriptive study on the management of asthma in MEA adult population. Data entry phase has been completed.

Cardiovascular-metabolic:

  • Egypt Cardio Risk Study: aims to identify the risk profile of patients with acute coronary syndromes in Egypt with subgroup analysis of diabetic and hypertensive patients. The project duration is 3 years.

Oncology:

  • The study aims to investigate the prevalence of EGFR mutation in Middle Eastern patients with lung cancer from Egypt.

Respiratory:

The objective of the study is to determine the potential physiological and clinical impact of “early” exercise training-related PR on the multidimensional aspects of dyspnea and exercise endurance in COPD patients after discharge from hospitalisation due to an acute exacerbation of chronic obstructive pulmonary disease (COPD).

Externally sponsored scientific research:

AstraZeneca recognizes the important role that Externally Sponsored Research can play in expanding the knowledge related to our products and/or its associated disease area(s). This research can advance science and contribute to the development of better medicines for patients consistent with the company’s overall research and global development strategy. The following studies are running currently:


Cardiovascular-metabolic:

  • Egypt Cardio Risk Study: aims to identify the risk profile of patients with acute coronary syndromes in Egypt with subgroup analysis of diabetic and hypertensive patients. The project duration is 3 years.

Oncology:

  • The study aims to investigate the prevalence of EGFR mutation in Middle Eastern patients with lung cancer from Egypt.

Respiratory:

The objective of the study is to determine the potential physiological and clinical impact of “early” exercise training-related PR on the multidimensional aspects of dyspnea and exercise endurance in COPD patients after discharge from hospitalisation due to an acute exacerbation of chronic obstructive pulmonary disease (COPD).



Affordability and Patient Support Programs

Patient Support Programs

  • The patient support arm of the I-Protect program supports patient education and early detection of diabetes complications (retinopathy, nephropathy & neuropathy).
  • Our oncology patient support program was implemented in 2015, the program fully sponsors the EGFR test for Egyptian patients diagnosed with metastatic lung cancer.
  • Our diabetes affordability program has a patient support arm, providing the patients with glucometer and lab tests to support monitoring and improve adherence to treatment.
  • Our Asthma patients support program implemented in 2015 where we educate patients about how to use the Turbohaler device.

Affordability Programs

AstraZeneca Egypt has launched affordability programs for diabetes and oncology products aiming at increasing patients’ access to innovative medicines, decreasing patients’ burden and improving adherence/compliance to medicines.



Patient Safety

In order to monitor the safety of AstraZeneca products, we encourage reporting any side effects experienced while taking an AstraZeneca product to the AZ Patient Safety Centre:

Phone: +20 2 25980205
Fax: +20 2 5980225
Email: Patient.SafetyEgypt@astrazeneca.com